Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback